Why CareDx Stock Jumped Today

CareDx (CDXS) jumped 14.72% after the precision medicine diagnostics company lifted its full-year revenue and earnings guidance. The firm reported adjusted net income of $20 million, or $0.37 per share, more than tripling prior results and crushing the Wall Street consensus of $0.23 per share by 61%.

The beat was powered by stronger demand for CareDx's non-invasive transplant monitoring tests and improved reimbursement trends. The Centers for Medicare & Medicaid Services affirmed coverage for the company's kidney, heart, and lung transplant surveillance testing, a tailwind that helped drive the upward revision to full-year targets.

CareDx specializes in diagnostic solutions that help clinicians monitor organ transplant rejection without invasive biopsies. The CMS coverage decision removes a key reimbursement overhang and validates the company's testing protocols across three major transplant categories.